An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (AD)

Phase 2

• Conditions: Alzheimer's Disease; Neurological - Alzheimer's disease

• Registration Number: ACTRN12612000869875
• Lead Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 1960

Inclusion Criteria

Mild to Moderate Alzheimer's Disease with an MMSE score between 15 and 26. Each subject must have a reliable and competent trial partner/caregiver who has
a close relationship with the subject

Exclusion Criteria

evidence of vascular dementia or stroke. Other clinically relevant neurological disorder. Clinically relevant or unstable psychiatric disorders. History of hepatitis or liver disease within the previous 6 months. History of malignancy occurring within the previous five years.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change from Baseline in ADAS-Cog score[78 weeks];change from Baseline in ADCS-ADL score[78 weeks]

Secondary Outcome Measures

Name	Time	Method
change-from-Baseline in CDR-SB score[78 weeks];change-from-Baseline in total hippocampal<br>volume using MRI.[78 weeks];change-from-Baseline in Cerebral Spinal Fluid total tau concentration by laboratory analysis[78 weeks]